Remove Bioinformatics Remove Disease Remove Immune Response
article thumbnail

Advancing vaccine design: potential of peptide mimicry

Drug Target Review

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine 98
article thumbnail

Not all neoantigens are created equal

Drug Target Review

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Neoantigens are recognised as non-self and trigger an immune response.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Transforming cancer treatment for greatest impact

Drug Target Review

Cancer is a disease driven by variable genetic mutations. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. The preclinical results demonstrated significant immune responses and tumour regression.

Treatment 106
article thumbnail

The first major set of genetic associations found in long COVID

Drug Target Review

Combinatorial analytics approaches identify combinations of features that together are associated with the disease phenotype in patient sub-groups, capturing the non-linear effects of interactions between multiple genes. The combinatorial approach is considerably more sensitive than GWAS and requires much smaller patient populations.

article thumbnail

Can Global Genomic Surveillance Forecast the Next Pandemic?

PLOS: DNA Science

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98
article thumbnail

Defense-Forward Biosecurity

Codon

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 84
article thumbnail

Latest news on drug repurposing in oncology #19

The Anticancer Fund

Secondary analyses looked at disease-free and overall survival, finding no differences between arms - suggesting no influence on disease progression of metformin in this patient population. Results showed no significant difference between the two arms, although the metformin arm showed favourable changes in metabolic parameters.

Drugs 52